Literature DB >> 8464877

Blockade of human immunodeficiency virus type 1 production in CD4+ T cells by an intracellular CD4 expressed under control of the viral long terminal repeat.

L Buonocore1, J K Rose.   

Abstract

A retroviral vector was constructed in which a gene encoding a mutated soluble CD4 protein that is retained in the endoplasmic reticulum (sCD4-KDEL) is expressed under control of human immunodeficiency virus type 1 (HIV-1) regulatory elements. HIV-1 infection of a human T-cell line transduced with this vector led to induction of sCD4-KDEL synthesis and a block in transport of the HIV envelope protein to the cell surface. There was a complete block to maturation of infectious HIV-1 in the transduced cells, no viral spread, and little or no syncytium formation. Infected cells gradually disappeared from the culture over a period of 2 months. This intracellular trap for HIV has potential application in gene therapy for AIDS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8464877      PMCID: PMC46162          DOI: 10.1073/pnas.90.7.2695

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Ribozymes as potential anti-HIV-1 therapeutic agents.

Authors:  N Sarver; E M Cantin; P S Chang; J A Zaia; P A Ladne; D A Stephens; J J Rossi
Journal:  Science       Date:  1990-03-09       Impact factor: 47.728

2.  Improved retroviral vectors for gene transfer and expression.

Authors:  A D Miller; G J Rosman
Journal:  Biotechniques       Date:  1989-10       Impact factor: 1.993

3.  Prevention of HIV-1 glycoprotein transport by soluble CD4 retained in the endoplasmic reticulum.

Authors:  L Buonocore; J K Rose
Journal:  Nature       Date:  1990-06-14       Impact factor: 49.962

Review 4.  Structure and function of the HIV envelope.

Authors:  J A McKeating; R L Willey
Journal:  AIDS       Date:  1989       Impact factor: 4.177

5.  Functional dissection of the HIV-1 Rev trans-activator--derivation of a trans-dominant repressor of Rev function.

Authors:  M H Malim; S Böhnlein; J Hauber; B R Cullen
Journal:  Cell       Date:  1989-07-14       Impact factor: 41.582

6.  HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus.

Authors:  D Trono; M B Feinberg; D Baltimore
Journal:  Cell       Date:  1989-10-06       Impact factor: 41.582

7.  Mutational analysis of the cleavage sequence of the human immunodeficiency virus type 1 envelope glycoprotein precursor gp160.

Authors:  E O Freed; D J Myers; R Risser
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

8.  Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector.

Authors:  V Karacostas; K Nagashima; M A Gonda; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

9.  The human immunodeficiency virus gp120 binding site on CD4: delineation by quantitative equilibrium and kinetic binding studies of mutants in conjunction with a high-resolution CD4 atomic structure.

Authors:  U Moebius; L K Clayton; S Abraham; S C Harrison; E L Reinherz
Journal:  J Exp Med       Date:  1992-08-01       Impact factor: 14.307

10.  A quantitative analysis of the endocytic pathway in baby hamster kidney cells.

Authors:  G Griffiths; R Back; M Marsh
Journal:  J Cell Biol       Date:  1989-12       Impact factor: 10.539

View more
  12 in total

1.  Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection.

Authors:  A G Yang; X Bai; X F Huang; C Yao; S Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

Review 2.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

3.  Misdirection of membrane trafficking by HIV-1 Vpu and Nef: Keys to viral virulence and persistence.

Authors:  Andrey Tokarev; John Guatelli
Journal:  Cell Logist       Date:  2011-05

4.  Homolog-scanning mutagenesis reveals poliovirus receptor residues important for virus binding and replication.

Authors:  M E Morrison; Y J He; M W Wien; J M Hogle; V R Racaniello
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

Review 5.  HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms.

Authors:  Amy Andrew; Klaus Strebel
Journal:  Mol Aspects Med       Date:  2010-09-19

6.  Reduction of HIV-1 infectivity through endoplasmic reticulum-associated degradation-mediated Env depletion.

Authors:  Antonio Casini; Michele Olivieri; Lara Vecchi; Oscar R Burrone; Anna Cereseto
Journal:  J Virol       Date:  2014-12-24       Impact factor: 5.103

7.  Lipopolysaccharide (LPS) down-regulates CD4 expression in primary human macrophages through induction of endogenous tumour necrosis factor (TNF) and IL-1 beta.

Authors:  G Herbein; A G Doyle; L J Montaner; S Gordon
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

8.  Combined intra- and extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody.

Authors:  S Y Chen; Y Khouri; J Bagley; W A Marasco
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

9.  Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation.

Authors:  M E Bromberg; W H Konigsberg; J F Madison; A Pawashe; A Garen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

Review 10.  Modulation of HIV-1-host interaction: role of the Vpu accessory protein.

Authors:  Mathieu Dubé; Mariana G Bego; Catherine Paquay; Éric A Cohen
Journal:  Retrovirology       Date:  2010-12-22       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.